BACKGROUND: Children with diffuse intrinsic pontine glioma (DIPG) continue to have poor outcomes, and radiotherapy (RT) is the only temporarily effective treatment. In this retrospective analysis, we studied the effect of time from diagnosis to start of RT on event-free survival (EFS) and overall survival (OS) in children with DIPG. METHODS: Records of children (n = 95) with DIPG treated with RT at a single institution between April 1999 and September 2009 were analyzed. RT was delivered at doses of 54.0-55.8 Gy at 1.8 Gy per fraction, and children were followed prospectively. The effect of gender, race, interruption during treatment course, age at diagnosis, duration of symptoms prior to diagnosis, use of protocol-based chemotherapy, and time from diagnosis to initiation of RT on EFS and OS was assessed by the Cox proportional hazards model. RESULTS: Time as a continuous variable from diagnosis to start of RT did not affect outcome. Time dichotomized to ≤14 days significantly affected OS (hazard ratio [HR] = 1.70, P = 0.014) and race other than white or black affected EFS (HR = 2.32, P = 0.017). The 95 patients had a 6-month EFS and OS of 60 ± 5% and 94.7 ± 2.3%, respectively, and a 12-month EFS and OS of 11.6 ± 3.1% and 49.5 ± 5%, respectively. CONCLUSIONS: Time as a continuous variable did not affect OS or EFS in our cohort; however, children treated within 2 weeks of diagnosis had poor outcomes. Although rapid initiation of RT is desirable, our findings do not support intensive efforts aimed at shortening delays from diagnosis to start of RT.
BACKGROUND:Children with diffuse intrinsic pontine glioma (DIPG) continue to have poor outcomes, and radiotherapy (RT) is the only temporarily effective treatment. In this retrospective analysis, we studied the effect of time from diagnosis to start of RT on event-free survival (EFS) and overall survival (OS) in children with DIPG. METHODS: Records of children (n = 95) with DIPG treated with RT at a single institution between April 1999 and September 2009 were analyzed. RT was delivered at doses of 54.0-55.8 Gy at 1.8 Gy per fraction, and children were followed prospectively. The effect of gender, race, interruption during treatment course, age at diagnosis, duration of symptoms prior to diagnosis, use of protocol-based chemotherapy, and time from diagnosis to initiation of RT on EFS and OS was assessed by the Cox proportional hazards model. RESULTS: Time as a continuous variable from diagnosis to start of RT did not affect outcome. Time dichotomized to ≤14 days significantly affected OS (hazard ratio [HR] = 1.70, P = 0.014) and race other than white or black affected EFS (HR = 2.32, P = 0.017). The 95 patients had a 6-month EFS and OS of 60 ± 5% and 94.7 ± 2.3%, respectively, and a 12-month EFS and OS of 11.6 ± 3.1% and 49.5 ± 5%, respectively. CONCLUSIONS: Time as a continuous variable did not affect OS or EFS in our cohort; however, children treated within 2 weeks of diagnosis had poor outcomes. Although rapid initiation of RT is desirable, our findings do not support intensive efforts aimed at shortening delays from diagnosis to start of RT.
Authors: Sridharan Gururangan; Susan N Chi; Tina Young Poussaint; Arzu Onar-Thomas; Richard J Gilbertson; Sridhar Vajapeyam; Henry S Friedman; Roger J Packer; Brian N Rood; James M Boyett; Larry E Kun Journal: J Clin Oncol Date: 2010-05-17 Impact factor: 44.544
Authors: David N Korones; Paul G Fisher; Cynthia Kretschmar; Tianni Zhou; Zhengjia Chen; James Kepner; Carolyn Freeman Journal: Pediatr Blood Cancer Date: 2008-02 Impact factor: 3.167
Authors: Kenneth J Cohen; Richard L Heideman; Tianni Zhou; Emiko J Holmes; Robert S Lavey; Eric Bouffet; Ian F Pollack Journal: Neuro Oncol Date: 2011-02-22 Impact factor: 12.300
Authors: Antony Michalski; Eric Bouffet; Roger E Taylor; Darren Hargrave; David Walker; Susan Picton; Kathryn Robinson; Barry Pizer; Sylwia Bujkiewicz Journal: J Neurooncol Date: 2010-03-19 Impact factor: 4.130
Authors: Daphne A Haas-Kogan; Anuradha Banerjee; Tina Young Poussaint; Mehmet Kocak; Michael D Prados; J Russell Geyer; Maryam Fouladi; Alberto Broniscer; Jane E Minturn; Ian F Pollack; Roger J Packer; James M Boyett; Larry E Kun Journal: Neuro Oncol Date: 2011-03 Impact factor: 12.300
Authors: C R Freeman; J P Krischer; R A Sanford; M E Cohen; P C Burger; R del Carpio; E C Halperin; L Munoz; H S Friedman; L E Kun Journal: Int J Radiat Oncol Biol Phys Date: 1993-09-30 Impact factor: 7.038
Authors: Alberto Broniscer; Justin N Baker; Michael Tagen; Arzu Onar-Thomas; Richard J Gilbertson; Andrew M Davidoff; Atmaram S Pai Panandiker; Atmaram Pai Panandiker; Wing Leung; Thomas K Chin; Clinton F Stewart; Mehmet Kocak; Christopher Rowland; Thomas E Merchant; Sue C Kaste; Amar Gajjar Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544